v3.26.1
Variable Interest Entities (Additional Information) (Details) - USD ($)
 3 Months Ended
Dec. 05, 2025
Apr. 17, 2025
Mar. 31, 2026
Mar. 02, 2026
Dec. 31, 2025
Sep. 30, 2025
Jun. 18, 2024
Variable Interest Entity [Line Items]              
Preferred Stock, Par or Stated Value Per Share     $ 0.0001   $ 0.0001    
Common stock, shares issued     8,491,267   7,033,004   3,250,000
Common stock, par value     $ 0.0001 $ 0.68 $ 0.0001    
Ownership Interest Rate   60.00%          
Additional paid-in capital     $ 799,301,000   $ 796,721,000    
Cash and cash equivalents     3,351,000   4,955,000    
Property and equipment, net     13,379,000   $ 13,599,000    
VIE [Member]              
Variable Interest Entity [Line Items]              
Equity Method Investment, Ownership Percentage 32.60% 60.00%          
Ownership Equity Interest Rate 32.60% 60.00%          
Vivasor [Member]              
Variable Interest Entity [Line Items]              
Preferred Stock, Shares Issued 6,101,468            
Net income for Scilex Bio attributable to the noncontrolling interest     1,500,000        
Cash and cash equivalents     2,900,000        
Property and equipment, net     12,600,000        
Accounts Payable     21,200,000        
Accrued Expenses     20,000,000        
NeuroBioGen Company [Member]              
Variable Interest Entity [Line Items]              
Aggregate amount payable under license agreements     4,800,000,000        
EAR SPV [Member] | Vivasor [Member]              
Variable Interest Entity [Line Items]              
Preferred Stock, Par or Stated Value Per Share $ 0.00001            
Payments to Acquire Businesses, Gross $ 9,000            
Scilex Bio JV [Member]              
Variable Interest Entity [Line Items]              
Common stock, shares issued   5,000,000          
Ownership Interest Rate   40.00%          
Historical carrying value of semnur shares   $ 0          
Percentage of estimated fair value expensed as in-process research and development   40.00%          
Estimated fair value expensed as in-process research and development net   $ 9,400,000          
In process research and development amount of estimated fair value   4,900,000          
Initial upfront payment due under the licensing arrangement recognised as current liability   1,100,000          
Additional paid-in capital as capital contribution   $ 1,800,000          
Net income for Scilex Bio attributable to the noncontrolling interest     22,400        
Aggregate amount payable under license agreements     6,500,000,000,000        
Upfront fee payable under license agreement     1,500,000,000        
Upfront fee payable under license agreement contingent upon the achievement of specified development, regulatory, and commercial milestone     $ 68,500,000,000        
Percentage of royalties on sales payable until expiration of licensed patent     5.00%        
Aggregate amount payable under license agreements capped amount     $ 6,500,000,000,000        
Upfront fee payable first tranche.     1,500,000,000        
Accounts Payable     100        
Accrued Expenses     1,100,000        
Scilex Bio JV [Member] | NeuroBioGen Company [Member]              
Variable Interest Entity [Line Items]              
Upfront fee payable under license agreement     1,100,000        
Upfront fee payable under license agreement contingent upon the achievement of specified development, regulatory, and commercial milestone     50,700,000        
Aggregate amount payable under license agreements capped amount     4,800,000,000        
Upfront fee payable first tranche.     1,100,000        
Scilex Bio JV [Member] | Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member]              
Variable Interest Entity [Line Items]              
Common stock, par value   $ 0.00001          
Semnur [Member]              
Variable Interest Entity [Line Items]              
Net income for Scilex Bio attributable to the noncontrolling interest     900,000        
Cash and cash equivalents     100,000        
Property and equipment, net     700,000        
Accounts Payable     6,400,000        
Accrued Expenses     $ 1,200,000        
Notes Payable           $ 800,000